Monkey/Chimp Anti-Sudan Ebola virus glycoprotein (GP) IgG ELISA Kit

Sample

Serum, plasma

Species Reactivity

Monkey/Chimp

Detection Method

iELISA

Intended Use

The Monkey Anti-Sudan Ebola Virus Glycoprotein (SUDV GP) IgG ELISA Kit is an indirect ELISA suitable for quantifying IgG antibody activity specific for Sudan Ebola glycoprotein in serum or plasma of vaccinated, immunized and/or infected hosts.

This immunoassay is suitable for:
Determining immune status relative to non-immune controls;
Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization and timing;
Qualifying and standardizing vaccine batches & protocols

The assay is for research use only (RUO) and is not intended nor validated for diagnosing Ebola virus disease (EVD). Reagents contain no virus or viral antigens.

Contents of Kit

1. Wash Solution Concentrate (100×): 10ml. Dilute the entire volume 10ml + 990ml with distilled or deionized water into a clean stock bottle. Label as Working Wash Solution and store at 4°C for long term and ambient temp. for short term.
2. Sample Diluent Concentrate (20×): 10ml. Dilute the entire volume, 10ml + 190ml with distilled or deionized water into a clean stock bottle. Label as Working Sample/Conjugate Diluent and store at 2-8°C until the kit lot expires or is used up.
3. Anti-Monkey IgG-HRP Conjugate Concentrate (100×): 0.15ml. Peroxidase conjugated anti-Monkey IgG in buffer with detergents and antimicrobial as stabilizers. Dilute fresh as needed; 10ul of concentrate to 1ml of Working Sample/Conjugate Diluent is sufficient for 1 8-well strip. Use within the working day and discard. Return 100× to 2-8°C storage.
4. SUDV GP Coated Strip Plate
5. Anti-SUDV GP Calibrators, 4vials×0.65ml. 1 U/ml, 2.5 U/ml, 5 U/ml, 10 U/ml.
6. Anti-SUDV GP Positive Control, 0.65 ml
7. Low NSB Sample Diluent, 30 ml
8. TMB Substrate, 12 ml
9. Stop Solution, 12 ml

Storage

The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label.

General Description

Ebola virus (EBOV) causes severe disease in humans and in nonhuman primates in the form of viral hemorrhagic fever.
Ebola Zaire attacks every organ and tissue in the human body except skeletal muscle and bone. Strains of Ebola include: Zaire, Sudan, Reston and Tai Forest. All cause illness in sub-human primates. Ebola Reston has not caused illness in humans. The mortality rate of Ebola victims is between 60-90%.
Ebola virions consist of seven structural proteins.. At the center is the helical ribonucleocapsid, which consists of the genomic RNA wrapped around a polymer of nucleoproteins (NP). Associated with the ribonucleoprotein is the RNA-dependent RNA polymerase (L) with the polymerase cofactor (VP35) and a transcription activator (VP30). The ribonucleoprotein is embedded in a matrix, formed by the major (VP40) and minor (VP24) matrix proteins. These particles are surrounded by a lipid membrane derived from the host cell membrane. The membrane anchors a glycoprotein (GP1,2) that projects 7 to 10 nm spikes away from its surface. While nearly identical to Marburg virions in structure, Ebola virions are antigenically distinct. Viral proteins (NP, GP, and VP40) are highly immunogenic and could individually or together constitute effective vaccines. Promising vaccine candidates include DNA vaccines or those based on adenoviruses, vesicular stomatitis Indiana virus (VSIV) or filovirus-like particles (VLPs) as all of these candidates could protect nonhuman primates from Ebola virus-induced disease.